Solvay and Petrovax combine ground breaking skills to produce new flu vaccines in Russia
Solvay Pharmaceuticals cell line to feed Petrovax production unit in Moscow
The two companies have also agreed to co-operate on research and development projects intended to result in next generation vaccines combining Solvay's and Petrovax's technologies. Solvay Pharmaceuticals has experience of manufacturing influenza vaccines in modern facilities in the Netherlands working to international good manufacturing practice (GMP) standards. It will contribute project implementation and management support during the construction of the new factory in Russia.
"We are proud of this alliance, which combines the achievements of Russian scientific research with the highest standards in manufacturing expertise and the most recent technologies developed by Solvay," said Sjirk Kok, Head of, Solvay Pharmaceuticals' Influenza business. "We expect that this agreement will further enhance our presence in Russia, which is already developing very well," he added.
The European Bank for Reconstruction and Development (EBRD) will grant a long term loan of EUR 15 million to Petrovax for the construction of the new facility.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.